ECT2抗体;ECT2 Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P12612(ECT2 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P12612(ECT2 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

**Background of ECT2 Antibody**

The epithelial cell transforming sequence 2 (ECT2) antibody is a research tool targeting the ECT2 protein, a critical regulator of cytokinesis and cell cycle progression. ECT2. a guanine nucleotide exchange factor (GEF), activates Rho GTPases (e.g., RhoA, Rac1) by promoting GTP binding, which is essential for contractile ring formation during mitotic exit. Structurally, ECT2 contains an N-terminal BRCT domain, which mediates phospho-dependent protein interactions, and a C-terminal GEF catalytic domain. Its activity is tightly regulated through phosphorylation and subcellular localization, particularly during mitosis.

Dysregulation of ECT2 is linked to cancer pathogenesis. Overexpression or aberrant activation of ECT2 disrupts cytokinesis, promotes genomic instability, and drives tumorigenesis in various cancers, including lung, breast, and glioblastoma. ECT2's oncogenic role is attributed to its Rho-GEF activity, which enhances cell proliferation, invasion, and metastasis. Consequently, ECT2 is considered a potential therapeutic target and prognostic biomarker.

The ECT2 antibody is widely used in molecular and cancer research to study ECT2 expression, localization, and function. It enables detection via techniques like Western blotting, immunofluorescence, and immunohistochemistry, aiding investigations into cell division mechanics, tumor progression, and drug response. Commercial ECT2 antibodies are typically validated for specificity against human, mouse, or rat homologs, supporting cross-species studies in both basic and translational research contexts.